These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17458165)

  • 21. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
    Fattal E; Bochot A
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1203-23. PubMed ID: 17097190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.
    Séguin RM; Ferrari N
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1505-17. PubMed ID: 19715448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
    Reischl D; Zimmer A
    Nanomedicine; 2009 Mar; 5(1):8-20. PubMed ID: 18640078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.
    Lie AK; Kristensen G
    Expert Rev Mol Diagn; 2008 Jul; 8(4):405-15. PubMed ID: 18598223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
    Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
    Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses.
    Jeantet D; Schwarzmann F; Tromp J; Melchers WJ; van der Wurff AA; Oosterlaken T; Jacobs M; Troesch A
    J Clin Virol; 2009 Jul; 45 Suppl 1():S29-37. PubMed ID: 19651366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes.
    Reyes-Gutiérrez P; Alvarez-Salas LM
    Oligonucleotides; 2009 Sep; 19(3):233-42. PubMed ID: 19732021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs.
    Zhang YC; Taylor MM; Samson WK; Phillips MI
    Methods Mol Med; 2005; 106():11-34. PubMed ID: 15375310
    [No Abstract]   [Full Text] [Related]  

  • 31. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HPV and cervical cancer: updates on an established relationship.
    Subramanya D; Grivas PD
    Postgrad Med; 2008 Nov; 120(4):7-13. PubMed ID: 19020360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
    Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
    ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antisense targeting to human papillomavirus 18 E6/E7 affects the proliferation and apoptosis of human cervical carcinoma: an in vitro experiment with HeLa cells].
    Sima N; Kong DB; Wang W; Lu YP; Wang SX; Ma D
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1618-21. PubMed ID: 17803852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of chronic hepatitis B virus infection: a promising approach using small interfering RNA (siRNA).
    Dwivedi M; Misra SP; Misra V; Waikhom RK; Bhatnagar M
    Natl Med J India; 2008; 21(3):123-7. PubMed ID: 19004143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivin: a new target for anti-cancer therapy.
    Ryan BM; O'Donovan N; Duffy MJ
    Cancer Treat Rev; 2009 Nov; 35(7):553-62. PubMed ID: 19559538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted delivery of small interfering RNA: approaching effective cancer therapies.
    Pirollo KF; Chang EH
    Cancer Res; 2008 Mar; 68(5):1247-50. PubMed ID: 18316585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.